Login / Signup

Olanzapine 5 mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy.

Xiu-Bei ChenTao LiLi-E LinQin LinSan-Gang Wu
Published in: Journal of oncology (2022)
Patients receiving olanzapine plus standard antiemetic therapy has excellent antiemetic effect in NPC patients receiving cisplatin-based concurrent chemoradiotherapy, and patients with olanzapine 5 mg have a similar antiemetic effect and lower adverse effects compared with those with olanzapine 10 mg.
Keyphrases
  • chemotherapy induced
  • locally advanced
  • rectal cancer
  • squamous cell carcinoma
  • stem cells
  • bone marrow